DIA 2023: Impact of Exclusionary Behaviors on Team Dynamics

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.

In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.

Breakout session at SCOPE Summit 2024 discusses the potential use of artificial intelligence to improve clinical trial strategy generation.

Interactive panel at SCOPE discussed the potential of utilizing artificial intelligence in clinical trials.

Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months; early results from admIRE study suggest similar outcomes.